Screening for Chronic Kidney Disease: Change of Perspective and Novel Developments

Overview

Journal Curr Opin Nephrol Hypertens

Specialties Cardiology & Vascular Diseases
Nephrology

Date 2024 Aug 13

PMID 39137037

Authors

Dominique van Mil

Lyanne M Kieneker

Hiddo J L Heerspink

Ron T Gansevoort

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Chronic kidney disease (CKD) is a serious health issue because of its rising global prevalence and its complications, such as kidney failure and cardiovascular disease (CVD). CKD is mainly diagnosed late or undiagnosed, delaying or missing the initiation of preventive interventions. Screening can prevent or delay progressive kidney function decline and CVD. This article reviews diagnostic tests and risk prediction developments for patients with CKD, highlights key evidence for targeted screening, and provides new insights into population-wide screening.

Recent Findings: Large cohort studies and clinical trial data established the strong association of albuminuria with CKD outcomes, supporting the role of albuminuria as target of CKD screening and treatment. Significant advances in both risk prediction of CKD and CVD in CKD patients and treatment options provided new evidence for the relevance and implications of CKD screening. Guidelines recommend targeted screening in high-risk patients, but evidence suggests limited adherence to guideline recommendations. More recently, population-wide screening has been investigated as another approach, showing potential effectiveness and cost-effectiveness.

Summary: There is increasing evidence for the methods, implications, and effectiveness of CKD screening. Implementing and optimizing screening strategies requires enhanced awareness and understanding of the possibilities for CKD screening within different healthcare systems.

References

Shlipak M, Tummalapalli S, Boulware L, Grams M, Ix J, Jha V . The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020; 99(1):34-47. DOI: 10.1016/j.kint.2020.10.012. View

Schroeder E, Yang X, Thorp M, Arnold B, Tabano D, Petrik A . Predicting 5-Year Risk of RRT in Stage 3 or 4 CKD: Development and External Validation. Clin J Am Soc Nephrol. 2016; 12(1):87-94. PMC: 5220646. DOI: 10.2215/CJN.01290216. View

Tangri N, Stevens L, Griffith J, Tighiouart H, Djurdjev O, Naimark D . A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011; 305(15):1553-9. DOI: 10.1001/jama.2011.451. View

Gansevoort R, Correa-Rotter R, Hemmelgarn B, Jafar T, Lambers Heerspink H, Mann J . Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013; 382(9889):339-52. DOI: 10.1016/S0140-6736(13)60595-4. View

Folkerts K, Petruski-Ivleva N, Comerford E, Blankenburg M, Evers T, Gay A . Adherence to Chronic Kidney Disease Screening Guidelines Among Patients With Type 2 Diabetes in a US Administrative Claims Database. Mayo Clin Proc. 2021; 96(4):975-986. DOI: 10.1016/j.mayocp.2020.07.037. View

Herrington W, Staplin N, Wanner C, Green J, Hauske S, Emberson J . Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2022; 388(2):117-127. PMC: 7614055. DOI: 10.1056/NEJMoa2204233. View

. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes Endocrinol. 2023; 12(1):39-50. PMC: 7615591. DOI: 10.1016/S2213-8587(23)00321-2. View

Grams M, Brunskill N, Ballew S, Sang Y, Coresh J, Matsushita K . The Kidney Failure Risk Equation: Evaluation of Novel Input Variables including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts. J Am Soc Nephrol. 2023; 34(3):482-494. PMC: 10103205. DOI: 10.1681/ASN.0000000000000050. View

Ferguson T, Ravani P, Sood M, Clarke A, Komenda P, Rigatto C . Development and External Validation of a Machine Learning Model for Progression of CKD. Kidney Int Rep. 2022; 7(8):1772-1781. PMC: 9366291. DOI: 10.1016/j.ekir.2022.05.004. View

10.

Okpechi I, Caskey F, Gaipov A, Tannor E, Noubiap J, Effa E . Early Identification of CKD-A Scoping Review of the Global Populations. Kidney Int Rep. 2022; 7(6):1341-1353. PMC: 9171699. DOI: 10.1016/j.ekir.2022.03.031. View

11.

Pouwels X, van Mil D, Kieneker L, Boersma C, van Etten R, Evers-Roeten B . Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease. EClinicalMedicine. 2024; 68:102414. PMC: 10827681. DOI: 10.1016/j.eclinm.2023.102414. View

12.

Sundstrom J, Bodegard J, Bollmann A, Vervloet M, Mark P, Karasik A . Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study. Lancet Reg Health Eur. 2022; 20:100438. PMC: 9459126. DOI: 10.1016/j.lanepe.2022.100438. View

13.

Waijer S, Gansevoort R, Heerspink H . Change in albuminuria as a surrogate endpoint. Curr Opin Nephrol Hypertens. 2019; 28(6):519-526. DOI: 10.1097/MNH.0000000000000541. View

14.

Heerspink H, Cherney D, Gafor A, Gorriz J, Pergola P, Tang S . Effect of Avenciguat on Albuminuria in Patients with CKD: Two Randomized Placebo-Controlled Trials. J Am Soc Nephrol. 2024; . PMC: 11387026. DOI: 10.1681/ASN.0000000000000418. View

15.

Visseren F, Mach F, Smulders Y, Carballo D, Koskinas K, Back M . 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34):3227-3337. DOI: 10.1093/eurheartj/ehab484. View

16.

Heerspink H, Greene T, Tighiouart H, Gansevoort R, Coresh J, Simon A . Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019; 7(2):128-139. DOI: 10.1016/S2213-8587(18)30314-0. View

17.

Gheewala P, Zaidi S, Jose M, Bereznicki L, Peterson G, Castelino R . Effectiveness of targeted screening for chronic kidney disease in the community setting: a systematic review. J Nephrol. 2017; 31(1):27-36. DOI: 10.1007/s40620-017-0375-0. View

18.

. Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403(10440):2204-2256. PMC: 11121021. DOI: 10.1016/S0140-6736(24)00685-8. View

19.

Chan L, Nadkarni G, Fleming F, McCullough J, Connolly P, Mosoyan G . Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease. Diabetologia. 2021; 64(7):1504-1515. PMC: 8187208. DOI: 10.1007/s00125-021-05444-0. View

20.

Galbraith L, Ronksley P, Barnieh L, Kappel J, Manns B, Samuel S . The See Kidney Disease Targeted Screening Program for CKD. Clin J Am Soc Nephrol. 2016; 11(6):964-972. PMC: 4891759. DOI: 10.2215/CJN.11961115. View